Bli medlem
Bli medlem

Du är här


Changes in AroCell's management

AroCell announces today that Professor Gunnar Steineck has been appointed interim Chief Medical Officer at AroCell. Gunnar has a long experience as a urologist/oncologist and has previously been a board member of AroCell. Gunnar will take up the position on August 6, 2020.

“I am very pleased that Gunnar is taking on this position. His experience and knowledge in oncology and urology are very valuable for AroCell and Gunnar has previously made significant contributions in his role as a board member and in specific consulting assignments ", says Michael Brobjer, CEO of AroCell
At the same time, AroCell announces that it has agreed with the current CMO, Cecilia Ahlin, to end her employment at AroCell. Cecilia began her employment at AroCell on May 1 and has during the summer been on leave at her own request. We wish Cecilia all the best in her continued clinical work.


Michael Brobjer, CEO
Telephone: +46(0)18 50 30 20

About AroCell

AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein concentrations in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North Growth Market with Redeye AB as Certified Adviser:, +46 (0)8 121 576 90. For more information;

This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2020-08-05 17:27 CEST.


Changes in AroCell's management

Författare AroCell

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.